Literature DB >> 32030722

Acute kidney injury in paediatric patients with sickle cell disease is associated with increased morbidity and resource utilization.

Meghan McCormick1, Troy Richardson2, Bradley A Warady3, Enrico M Novelli4, Ramasubramanian Kalpatthi1.   

Abstract

Renal disease is a common complication experienced by patients with sickle cell disease (SCD), though the epidemiology of acute kidney injury (AKI) in paediatric patients and its impact on long-term renal outcomes is unclear. We utilized the Pediatric Health Information System (PHIS) to identify inpatient encounters of paediatric patients with SCD admitted for vaso-occlusive pain crisis (VOC). Overall, 1·4% of patients experienced at least one episode of AKI and 2·5% of admissions were complicated by AKI. Patients with at least one episode of AKI were more likely to be adolescents or young adults at the time of their initial admission, had increased rates of admission to the ICU, longer lengths of stay, increased costs of hospitalization, increased risk of readmission and increased rates of SCD-related comorbidities. Generalized estimating equation modelling demonstrated that increasing age, history of hypertension, history of haematuria and history of chronic kidney disease were associated with increased odds of developing AKI, though hydroxycarbamide use (OR 0·64, 95% CI 0·44-0·94) was protective. Episodes of AKI during hospitalization in children with SCD are associated with increased morbidity and utilization of hospital resources. Increasing the use of hydroxycarbamide may decrease the likelihood of this complication.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  Epidemiology; acute kidney injury; hydroxycarbamide; paediatric; sickle cell disease

Year:  2020        PMID: 32030722     DOI: 10.1111/bjh.16384

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  The nephropathy of sickle cell trait and sickle cell disease.

Authors:  Kenneth I Ataga; Santosh L Saraf; Vimal K Derebail
Journal:  Nat Rev Nephrol       Date:  2022-02-21       Impact factor: 42.439

2.  Neutrophil gelatinase-associated lipocalin is elevated in children with acute kidney injury and sickle cell anemia, and predicts mortality.

Authors:  Anthony Batte; Sahit Menon; John M Ssenkusu; Sarah Kiguli; Robert Kalyesubula; Joseph Lubega; Zachary Berrens; Edrisa Ibrahim Mutebi; Rodney Ogwang; Robert O Opoka; Chandy C John; Andrea L Conroy
Journal:  Kidney Int       Date:  2022-06-17       Impact factor: 18.998

3.  Acute kidney injury in hospitalized children with sickle cell anemia.

Authors:  Anthony Batte; Sahit Menon; John Ssenkusu; Sarah Kiguli; Robert Kalyesubula; Joseph Lubega; Edrisa Ibrahim Mutebi; Robert O Opoka; Chandy C John; Michelle C Starr; Andrea L Conroy
Journal:  BMC Nephrol       Date:  2022-03-18       Impact factor: 2.388

4.  Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis.

Authors:  Zachary Baldwin; Boshen Jiao; Anirban Basu; Joshua Roth; M A Bender; Zizi Elsisi; Kate M Johnson; Emma Cousin; Scott D Ramsey; Beth Devine
Journal:  Pharmacoecon Open       Date:  2022-04-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.